Bicalutamide: Difference between revisions

Revision as of 13:51, 7 January 2024 view source Alexander Berchansky (talk \| contribs) 29,726 edits No edit summary ← Older edit		Revision as of 13:52, 7 January 2024 view source Alexander Berchansky (talk \| contribs) 29,726 edits No edit summary Newer edit →
Line 1:		Line 1:
	<StructureSection load='~~1stp~~' size='340' side='right' caption='Caption for this structure' scene=''>		<StructureSection load='' size='340' side='right' caption='Caption for this structure' scene=''>
	<scene name='54/543362/Bicalutamide_in_ar/3'>R-Bicalutamide</scene>, marketed as Casodex <ref name="ARA prostate">PMID: 24639562</ref><ref name="nonsteroidal">PMID: 16841196</ref>, is one of the most stable and tolerated ARA used in the treatment of prostate cancer <ref name="ARA prostate" /><ref name="bicalutamide">PMID: 15833816</ref><ref name="AAWS">PMID: 28971898</ref>, belonging to the first generation of antiandrogens developed <ref name="ARA prostate" /><ref name="MoA">PMID: 35245614</ref>.		<scene name='54/543362/Bicalutamide_in_ar/3'>R-Bicalutamide</scene>, marketed as Casodex <ref name="ARA prostate">PMID: 24639562</ref><ref name="nonsteroidal">PMID: 16841196</ref>, is one of the most stable and tolerated ARA used in the treatment of prostate cancer <ref name="ARA prostate" /><ref name="bicalutamide">PMID: 15833816</ref><ref name="AAWS">PMID: 28971898</ref>, belonging to the first generation of antiandrogens developed <ref name="ARA prostate" /><ref name="MoA">PMID: 35245614</ref>.

Navigation menu